| Report ID | Date of report | Patient age | Patient gender |
| 111085 | May, 5, 2006 | 50 | Female |
List of drugs the patient takes:
| Drug | Ingredient(s) |
Vioxx | rofecoxib |
Butisol Sodium | butabarbital sodium |
Flexeril | cyclobenzaprine hydrochloride |
Celebrex | celecoxib |
Klonopin | clonazepam |
Vistaril | hydroxyzine hydrochloride |
| Name |
Anxiety |
Candidiasis |
Cerebrovascular Accident |
Chest Pain |
Chronic Obstructive Pulmonary Disease |
Conversion Disorder |
Convulsion |
Depression |
Dermal Cyst |
Difficulty In Walking |
Dyspnoea |
Fatigue |
Headache |
Heat Stroke |
Hypoxia |
Joint Effusion |
Joint Sprain |
Muscle Contractions Involuntary |
Myocardial Infarction |
Myoclonus |
Osteitis Deformans |
Osteopenia |
Osteoporosis |
Overdose |
Post-traumatic Stress Disorder |
Sinusitis |
Speech Disorder |
Results from eHealthMe : 3 report(s)
Comparison with the patient:
| Name | Count (% of total reports) |
Anxiety | 3 (100.00%) |
Candidiasis | 3 (100.00%) |
Cerebrovascular Accident | 3 (100.00%) |
Chest Pain | 3 (100.00%) |
Chronic Obstructive Pulmonary Disease | 3 (100.00%) |
Conversion Disorder | 3 (100.00%) |
Convulsion | 3 (100.00%) |
Depression | 3 (100.00%) |
Dermal Cyst | 3 (100.00%) |
Difficulty In Walking | 3 (100.00%) |
Dyspnoea | 3 (100.00%) |
Fatigue | 3 (100.00%) |
Headache | 3 (100.00%) |
Heat Stroke | 3 (100.00%) |
Hypoxia | 2 (66.67%) |
Joint Effusion | 3 (100.00%) |
Joint Sprain | 3 (100.00%) |
Muscle Contractions Involuntary | 3 (100.00%) |
Myocardial Infarction | 3 (100.00%) |
Myoclonus | 3 (100.00%) |
Osteitis Deformans | 3 (100.00%) |
Osteopenia | 3 (100.00%) |
Osteoporosis | 3 (100.00%) |
Overdose | 3 (100.00%) |
Post-traumatic Stress Disorder | 2 (66.67%) |
Sinusitis | 3 (100.00%) |
Speech Disorder | 3 (100.00%) |
Top 3 (total: 0. Click here to see more) co-used drugs - potential interacting drugs:
Death reported: 0
| Name | Count (% of total reports) |
Myocardial Infarction | 3 (100.00%) |
Myoclonus | 3 (100.00%) |
Muscle Contractions Involuntary | 3 (100.00%) |
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Recent drug risk analysis reports:
